Loading menu...

Prostate Cancer (PCa) will affect most men if they live long enough and PCa is one of the leading causes of cancer deaths.

 
Each year over 200,000 men are newly diagnosed with PCa in North America.  CPC-100 is for asympto-matic 'watchfull waiting' PCa patients who fail prostate removal & hormone therapy, with no approved drug availble to them. 

Drugs for  therapy-resitant solid cancers & hypoxic conditions 

 Colby's mission is to develop & sell drugs for hypoxia & therapy-resistant tumors

Colby drugs resore therapy-sensitivity or normoxia
Craig Heim, MBA

Board Observer for the Wisconsin Alumni Research Foundation (WARF)

Craig Heim provides corporate finance and analytical support for WARF and is a Colby Board Observer. He has 7 years of merger and acquisition, capital fundraising, and licensing experience as an investment banker. As a Vice President at Grace Matthews, a Milwaukee investment banking firm, Mr. Heim operated as an Investment Banker in sell-side, buy-side, and recapitalization transactions ranging from $20 to $300 million in size and held positions on boards of directors. Prior to joining Grace Matthews, Mr. Heim spent five years in operations management with International Paper. 

Mr. Heim is providing assistance to Colby as an existing WARF start-up and identifies opportunities through consultation on financial and legal resources, business planning and business management. WARF has long stood out among universities licensing their technology to outside companies and it has built a billion dollar endowment.

Mr. Heim holds both an M.B.A. from the Weinert Applied Ventures in Entrepreneurship program and a B.S. in Chemical Engineering (with Honors) from the University of Wisconsin – Madison.